Scarica l'app Stockscreener
43.16
0.82%
0.35
Dopo l'orario di chiusura:
43.50
0.34
+0.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$42.81
Aprire:
$42.57
Volume 24 ore:
1.02M
Relative Volume:
0.59
Capitalizzazione di mercato:
$2.32B
Reddito:
-
Utile/perdita netta:
$-38.99M
Rapporto P/E:
-14.40
EPS:
-2.9966
Flusso di cassa netto:
$-24.94M
1 W Prestazione:
-1.30%
1M Prestazione:
-9.42%
6M Prestazione:
-50.09%
1 anno Prestazione:
-7.80%
Intervallo 1D:
$41.76
$43.22
Intervallo di 1 settimana:
$41.76
$44.50
Portata 52W:
$39.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Nome
Soleno Therapeutics Inc
Settore
Industria
Telefono
650-213-8444
Indirizzo
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Confronta SLNO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
43.16 | 2.30B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-10-07 | Iniziato | Goldman | Buy |
| 2025-08-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-23 | Iniziato | TD Cowen | Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2024-12-02 | Reiterato | Robert W. Baird | Outperform |
| 2024-12-02 | Reiterato | Stifel | Buy |
| 2024-09-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-10 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-05 | Iniziato | Piper Sandler | Overweight |
| 2024-01-23 | Iniziato | Stifel | Buy |
| 2023-11-21 | Ripresa | Guggenheim | Buy |
| 2020-09-29 | Iniziato | Guggenheim | Buy |
| 2020-01-10 | Iniziato | Craig Hallum | Buy |
| 2019-12-23 | Iniziato | Oppenheimer | Outperform |
| 2018-02-13 | Reiterato | Maxim Group | Buy |
Mostra tutto
Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie
Solena Therapeutics (SLNO) Stock Under Pressure But Upside is Huge - Insider Monkey
Soleno Therapeutics (SLNO) Stock Analysis: Unveiling a Potential 164% Upside in the Biotech Arena - directorstalkinterviews.com
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Liquidity Mapping Around (SLNO) Price Events - Stock Traders Daily
Soleno Therapeutics Updates Executive Compensation and Severance Plans - TipRanks
Is Soleno Therapeutics, Inc. (NASDAQ:SLNO) The Best Under $50 Stock to Buy Now? - Insider Monkey
Emerald Mutual Fund Advisers Trust Reduces Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside - Finviz
Soleno Therapeutics (SLNO) Valuation Checked After New Q4 2025 Revenue Guidance - Sahm
FY2025 Earnings Estimate for SLNO Issued By HC Wainwright - MarketBeat
Emerald Advisers LLC Trims Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
SLNO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Soleno Therapeutics, Inc. - ACCESS Newswire
Q2 EPS Estimate for Soleno Therapeutics Increased by Analyst - MarketBeat
Soleno Therapeutics stock price target raised to $120 from $110 at H.C. Wainwright - Investing.com Nigeria
Soleno Therapeutics stock price target raised to $120 from $110 at H.C. Wainwright By Investing.com - Investing.com South Africa
Soleno Therapeutics (SLNO): Wells Fargo Raises Price Target to $114 | SLNO Stock News - GuruFocus
Johnson Fistel Begins Investigation on Behalf of Soleno - GlobeNewswire
Wells Fargo Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $114 - 富途资讯
Soleno Therapeutics (SLNO) may find a bottom soon, here's why you should buy the stock now - MSN
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring A 160% Potential Upside - directorstalkinterviews.com
SLNO INVESTOR ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Fraud Investigation - GlobeNewswire
Momentum Shift: What is Soleno Therapeutics Incs revenue forecast2025 Year in Review & Consistent Growth Equity Picks - baoquankhu1.vn
Market Outlook: Is Soleno Therapeutics Inc forming a breakout patternJuly 2025 Momentum & Long Hold Capital Preservation Plans - baoquankhu1.vn
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid - GlobeNewswire
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman - GlobeNewswire Inc.
Dow Update: Is Monogram Technologies Inc trading at a discountWeekly Stock Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Q4 EPS Estimate for Soleno Therapeutics Increased by Analyst - MarketBeat
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Soleno Therapeutics: Why I’m Staying On The Sidelines (NASDAQ:SLNO) - Seeking Alpha
Jobs Data: Is Soleno Therapeutics Inc in a bullish channel2025 Earnings Impact & Trade Opportunity Analysis - baoquankhu1.vn
Relative Strength Alert For Soleno Therapeutics - Nasdaq
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock - Investing.com
A Look At Soleno Therapeutics (SLNO) Valuation After Profitable Q4 2025 And VYKAT XR Adoption - Sahm
Baird lowers Soleno Therapeutics stock price target to $107 on new starts trajectory - Investing.com Nigeria
Wall Street Recap: Will Soleno Therapeutics Inc. stock see insider buyingWeekly Investment Summary & Reliable Breakout Forecasts - Bộ Nội Vụ
Soleno Therapeutics (NASDAQ:SLNO) Hits New 1-Year LowTime to Sell? - MarketBeat
Soleno Therapeutics stock hits 52-week low at 41.47 USD By Investing.com - Investing.com Nigeria
Soleno reports $189-191 million in 2025 VYKAT XR sales since launch - Investing.com Nigeria
SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc. - marketscreener.com
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap UpTime to Buy? - MarketBeat
Soleno Therapeutics stock falls despite revenue beat as patient starts decline - Investing.com UK
Rally Mode: Will Soleno Therapeutics Inc stock deliver shareholder valueWeekly Investment Report & Technical Entry and Exit Tips - Bộ Nội Vụ
Soleno Therapeutics stock hits 52-week low at 41.47 USD - Investing.com
Soleno Therapeutics up on forecasting preliminary 2025 Vykat XR sales above estimates - TradingView — Track All Markets
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Potential Upside of 164% Captures Investor Attention - DirectorsTalk Interviews
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results - The Manila Times
SLNOSoleno Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Market Review: Why Soleno Therapeutics Inc stock is popular among millennialsWeekly Profit Report & Long-Term Capital Growth Strategies - moha.gov.vn
Peregrine Capital Management LLC Makes New Investment in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics Inc Azioni (SLNO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):